<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with high <z:hpo ids='HP_0000739'>anxiety</z:hpo> sensitivity (AS) become extremely anxious with heart rate increases, <z:hpo ids='HP_0001962'>palpitations</z:hpo>, and symptoms of psychological arousal </plain></SENT>
<SENT sid="1" pm="."><plain>AS predicts <z:e sem="disease" ids="C0086769" disease_type="Mental or Behavioral Dysfunction" abbrv="">panic attacks</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF), AS correlates with symptom preoccupation and reduced quality of life </plain></SENT>
<SENT sid="3" pm="."><plain>We assessed whether AS is associated with outcomes of rhythm-control versus rate-control in <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) patients with AF </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND RESULTS: Before random assignment, 933 participants (172 women) in the <z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo> and <z:hpo ids='HP_0001635'>Congestive Heart Failure</z:hpo> Trial completed the <z:hpo ids='HP_0000739'>Anxiety</z:hpo> Sensitivity Inventory (ASI) </plain></SENT>
<SENT sid="5" pm="."><plain>Cox proportional hazards models showed no main effects of treatment (P=0.61) or AS (P=0.72) for time to cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, but these factors interacted significantly (P=0.020) </plain></SENT>
<SENT sid="6" pm="."><plain>High AS patients (upper quartile, ASI ≥33) randomly assigned to rhythm-control had significantly lower cardiovascular mortality than those receiving rate-control (hazard ratio, 0.54; 95% confidence interval, 0.32-0.93; P=0.022) </plain></SENT>
<SENT sid="7" pm="."><plain>With lower ASI scores (&lt;33), treatments did not differ (hazard ratio, 1.12; 95% confidence interval, 0.83-1.51; P=0.46) </plain></SENT>
<SENT sid="8" pm="."><plain>The interaction between treatment and dichotomized ASI scores remained significant (P=0.009) after adjustment for covariates including age, sex, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:chebi fb="0" ids="16737">creatinine</z:chebi>, ejection fraction, time since first diagnosis of AF, New York Heart Association functional class, <z:hpo ids='HP_0000716'>depression</z:hpo> symptoms, marital status, and baseline β-blockers, <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi>, oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, and implantable cardioverter-defibrillators </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> and <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> patients with high AS had better long-term prognosis with rhythm- than rate-control </plain></SENT>
<SENT sid="10" pm="."><plain>If replicated, AS should be considered in treatment selection </plain></SENT>
<SENT sid="11" pm="."><plain>Research is also needed concerning mechanisms and possible joint AS-AF treatments </plain></SENT>
<SENT sid="12" pm="."><plain>CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov </plain></SENT>
<SENT sid="13" pm="."><plain>Unique identifier: NCT88597077 </plain></SENT>
</text></document>